ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
ImmunityBio (NASDAQ: IBRX) has secured a $75 million equity financing through a registered direct offering with a single institutional investor. The agreement includes the issuance of common stock and warrants for additional share purchases. If the warrants are fully exercised, they could generate up to approximately $90 million in additional gross proceeds.
The securities will be offered under the company's automatic shelf registration statement on Form S-3, with a final prospectus supplement to be filed with the SEC. The financing aims to provide working capital and support ongoing business operations.
ImmunityBio (NASDAQ: IBRX) ha ottenuto un finanziamento azionario di 75 milioni di dollari attraverso un'offerta diretta registrata con un singolo investitore istituzionale. L'accordo prevede l'emissione di azioni ordinarie e warrant per ulteriori acquisti di azioni. Se i warrant vengono completamente esercitati, potrebbero generare fino a circa 90 milioni di dollari in proventi lordi aggiuntivi.
I titoli saranno offerti sotto la registrazione automatica della società sulla forma S-3, con un supplemento finale del prospetto da presentare alla SEC. Il finanziamento mira a fornire capitale circolante e supportare le operazioni aziendali in corso.
ImmunityBio (NASDAQ: IBRX) ha asegurado un financiamiento de capital de 75 millones de dólares a través de una oferta directa registrada con un único inversor institucional. El acuerdo incluye la emisión de acciones ordinarias y warrants para compras adicionales de acciones. Si los warrants se ejercen completamente, podrían generar hasta aproximadamente 90 millones de dólares en ingresos brutos adicionales.
Los valores se ofrecerán bajo la declaración de registro automática de la compañía en el Formulario S-3, con un suplemento de prospecto final que se presentará a la SEC. El financiamiento tiene como objetivo proporcionar capital de trabajo y apoyar las operaciones comerciales en curso.
ImmunityBio (NASDAQ: IBRX)는 단일 기관 투자자를 통해 등록된 직접 공모를 통해 7500만 달러의 자본 조달을 확보했습니다. 이 계약에는 보통주 및 추가 주식 구매를 위한 워런트 발행이 포함됩니다. 워런트가 완전히 행사될 경우, 약 9000만 달러의 추가 총 수익을 생성할 수 있습니다.
증권은 회사의 자동 선반 등록 성명서인 S-3 양식에 따라 제공되며, SEC에 최종 투자 설명서 보충이 제출될 예정입니다. 이 자금 조달은 운영 자본을 제공하고 지속적인 사업 운영을 지원하는 것을 목표로 합니다.
ImmunityBio (NASDAQ: IBRX) a sécurisé un financement en capital de 75 millions de dollars par le biais d'une offre directe enregistrée avec un seul investisseur institutionnel. L'accord comprend l'émission d'actions ordinaires et de bons de souscription pour des achats d'actions supplémentaires. Si les bons de souscription sont entièrement exercés, ils pourraient générer jusqu'à environ 90 millions de dollars de produits bruts supplémentaires.
Les titres seront offerts dans le cadre de la déclaration d'enregistrement automatique de la société sur le formulaire S-3, avec un supplément de prospectus final à déposer auprès de la SEC. Le financement vise à fournir du capital de travail et à soutenir les opérations commerciales en cours.
ImmunityBio (NASDAQ: IBRX) hat eine Eigenkapitalfinanzierung in Höhe von 75 Millionen Dollar durch ein registriertes Direktangebot mit einem einzigen institutionellen Investor gesichert. Die Vereinbarung umfasst die Ausgabe von Stammaktien und Warrants für zusätzliche Aktienkäufe. Wenn die Warrants vollständig ausgeübt werden, könnten sie bis zu etwa 90 Millionen Dollar an zusätzlichen Bruttoeinnahmen generieren.
Die Wertpapiere werden im Rahmen der automatischen Shelf-Registrierungserklärung des Unternehmens auf dem Formular S-3 angeboten, mit einem endgültigen Prospektzusatz, der bei der SEC eingereicht wird. Die Finanzierung zielt darauf ab, Betriebskapital bereitzustellen und den laufenden Geschäftsbetrieb zu unterstützen.
- Secured $75 million in immediate financing
- Potential for additional $90 million through warrant exercise
- Single institutional investor indicates strong confidence
- Potential shareholder dilution from new stock issuance
- Additional dilution possible if warrants are exercised
The securities to be sold by the Company are offered under its automatic shelf registration statement on Form S-3 (Registration No. 333-278770). A final prospectus supplement, which contains additional information relating to the offering, will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit ImmunityBio.com (Founder’s Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the timing and size of the proposed offering, the potential exercise of the warrants being offered and resulting additional proceeds to the Company, the anticipated closing of the equity financing described herein and use of proceeds to be received from such financing, the application of the Company’s science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that reduce or eliminate the need for standard high-dose chemotherapy. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) whether the equity financing transaction described herein will close on the timeline anticipated, if at all, (ii) those related to the regulatory submission, filing and review process and the timing thereof, (iii) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (iv) whether clinical trials will result in registrational pathways, (v) whether clinical trial data will be accepted by regulatory agencies, (vi) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vii) potential delays in product availability, regulatory approvals, and reimbursement decisions, (viii) ImmunityBio’s ability to retain and hire key personnel, (ix) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (x) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xi) ImmunityBio’s ability to successfully commercialize its approved product and product candidates, (xii) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiii) ImmunityBio’s ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading “Risk Factors” in the Company’s Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20250408525635/en/
Investors
Hemanth Ramaprakash, PhD, MBA
+1-858-746-9289
Hemanth.Ramaprakash@ImmunityBio.com
Media
Sarah Singleton
+1-415-290-8045
Sarah.Singleton@ImmunityBio.com
Source: ImmunityBio, Inc.
FAQ
How much funding did ImmunityBio (IBRX) secure in its latest equity financing?
What type of securities are included in IBRX's $75 million financing deal?
What is the purpose of ImmunityBio's $75 million equity financing?
How will ImmunityBio's new equity financing be registered?
